LENSAR

LENSAR Equity

The The Equity of LENSAR (LNSR) as of Oct 21, 2026 is -26.02 M USD. In the previous year, The Equity was 18.65 M USD — a change of -239.54% (lower).

Equity

-26.02 MUSD

YoY

-239.54%

Last updated:

In 2025, LENSAR's equity was -26.02 M USD, a -239.54% increase from the 18.65 M USD equity in the previous year.

The LENSAR Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-20.47 M USD
Jan 1, 2019
-30.55 M USD
Jan 1, 2020
67.21 M USD
Jan 1, 2021
54.88 M USD
Jan 1, 2022
41.98 M USD
Jan 1, 2023
47.18 M USD
Jan 1, 2024
18.65 M USD
Jan 1, 2025
-26.02 M USD
The LENSAR Equity history
YEAREquityYoY
-26.02 MUSD-239.54%
18.65 MUSD-60.48%
47.18 MUSD+12.37%
41.98 MUSD-23.50%
54.88 MUSD-18.35%
67.21 MUSD-319.98%
-30.55 MUSD+49.29%
-20.47 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR, Inc. generates revenue through the sale of its femtosecond laser systems, specifically the LENSAR Laser System with Streamline IV and IntelliAxis, and the ALLY Adaptive Cataract Treatment System. The LENSAR Laser System includes disposable patient interface device kits as consumables, which contribute to recurring revenue. Surgeons and ophthalmic clinics purchasing these systems form the primary customer segment, utilizing the technology for cataract surgery and corneal astigmatism management. The company's focus on proprietary technologies ensures differentiation in the medical device market. The ALLY System is marketed as a compact solution for femtosecond laser assisted cataract procedures, designed to streamline surgical workflows within a single operating room. Its product portfolio emphasizes integrated features that enhance visual outcomes for patients. The consumable components, such as the disposable patient interface device kits, support ongoing revenue streams alongside the initial system sales. These offerings target healthcare providers seeking advanced surgical tools for refractive cataract surgery. LENSAR's business model relies on selling high-precision medical devices to specialized healthcare facilities. The LENSAR Laser System and ALLY System are positioned as premium solutions for cataract treatment, with the consumables providing sustained revenue opportunities. The company's product development centers around improving surgical efficiency and patient visual results through its patented technologies. LENSAR is one of the most popular companies on Eulerpool.

Equity Details

Analyzing LENSAR's Equity

LENSAR's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding LENSAR's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating LENSAR's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

LENSAR's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in LENSAR’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about LENSAR stock

The Equity of LENSAR is -26.02 M USD in 2025.

The Equity of LENSAR changed from 18.65 M USD to -26.02 M USD, representing a -239.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity LENSAR since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's LENSAR historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — LENSAR

All Key Metrics — LENSAR